Aarti Pharmalabs shares jumped more than 7% in early trade on Tuesday after reports suggested that the US Food and Drug Administration (FDA) has approached Indian pharmaceutical manufacturers to help address a shortage of the critical cancer treatment drug ifosfamide in the United States.
According to media reports, the US FDA is exploring alternative supply sources for ifosfamide, a widely used chemotherapy medicine that is currently facing shortages due to manufacturing disruptions. The move is aimed at ensuring uninterrupted availability of the drug for cancer patients across the US.
The development has placed Aarti Pharmalabs in the spotlight as the company manufactures the active pharmaceutical ingredient (API) used in the production of ifosfamide. Market participants are closely tracking the potential opportunities that could emerge if procurement from Indian suppliers increases.
Aarti Pharmalabs holds a unique position in the domestic pharmaceutical industry, as it is currently the only Indian company with a Drug Master File (DMF) registered for ifosfamide API in the US FDA database. A DMF is a confidential submission that provides detailed information about the manufacturing process, quality systems, and production facilities associated with pharmaceutical ingredients.
Investor sentiment strengthened following the reports, with the stock witnessing strong buying interest during the morning session. As of 10:08 AM, Aarti Pharmalabs shares touched an intraday high of Rs 735, compared to the previous close of Rs 678. The stock opened at Rs 680.80 and traded between Rs 680.80 and Rs 735 during the session. Trading volumes also remained robust, with over 6.06 lakh shares changing hands.